Davis Gregory D 4
4 · SANGAMO THERAPEUTICS, INC · Filed Jan 26, 2026
Research Summary
AI-generated summary of this filing
Sangamo (SGMO) Head of Research Gregory Davis Surrenders 7,721 Shares
What Happened
- Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics (SGMO), had 7,721 shares withheld on January 22, 2026 to satisfy mandatory tax withholding related to vested restricted stock units (RSUs). The shares were valued using the issuer's closing price of $0.3985 per share, resulting in proceeds of approximately $3,077. This was a tax-withholding disposition to the company (reporting code F), not an open-market sale.
Key Details
- Transaction date and price: January 22, 2026; $0.3985 per share (issuer closing price).
- Shares surrendered: 7,721; reported value ≈ $3,077.
- Shares owned after transaction: the filing does not state a single total explicitly; it notes vested and outstanding RSU components (see footnotes below).
- Notable footnotes:
- F1: Shares were surrendered solely for mandatory tax withholding and this disposition is to the issuer for reporting purposes, not a discretionary market sale.
- F2: Breakdown of RSU holdings referenced in the filing: 11,029 shares from a Jan 22, 2024 RSU vesting installment, 2,022 shares from a Feb 24, 2023 RSU grant (vesting through Feb 24, 2026), and 49,726 shares from a Feb 25, 2025 RSU grant (with future vesting schedule).
- F3: Includes 5,000 shares acquired under the 2020 Employee Stock Purchase Plan.
- F4: Reporting person previously transferred 8 shares to an ex-spouse (no longer beneficially owned).
- Timeliness: Transaction occurred Jan 22, 2026; Form 4 filed Jan 26, 2026 (within the standard two-business-day reporting window).
Context
- This was a routine tax-withholding event tied to RSU vesting (a common administrative transaction). It does not represent a discretionary sale or purchase and should not be interpreted alone as a signal of insider sentiment.
Insider Transaction Report
Form 4
Davis Gregory D
Head of Research & Technology
Transactions
- Tax Payment
Common Stock
[F1][F2][F3][F4]2026-01-22$0.40/sh−7,721$3,077→ 191,062 total
Footnotes (4)
- [F1]Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
- [F2]Includes: (a) 11,029 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 2,022 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
- [F3]Includes 5,000 shares acquired on May 30, 2025 under the Issuer's 2020 Employee Stock Purchase Plan.
- [F4]The Reporting Person previously transferred 8 shares of the Issuer's common stock to his ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
Signature
/s/ Scott Willoughby, Attorney-in-Fact|2026-01-26